PAHC PHIBRO ANIMAL HEALTH CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 1069899 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.1%
TTM net income YoY51.5%
TTM EPS YoY49.7%
Revenue 3-yr CAGR16.4%
Net income 3-yr CAGR70.5%
Margins
Gross margin33.8%
Operating margin12.5%
Net margin6.7%
FCF margin1.4%
EBITDA margin15.9%
Returns
ROE28.2%
ROA7.1%
ROIC (approx.)15.6%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets72.4%
Debt / equity1.46x
Current ratio3.20x
Interest coverage4.18x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio1.2%
Payout ratio19.0%
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $386.77M | $396.75M | $383.54M | $373.91M | $363.89M | $378.70M | $347.82M | $309.26M |
| Cost of revenue | $258.24M | $262.35M | $257.87M | $241.25M | $244.11M | $268.69M | $243.26M | $207.39M |
| Gross profit | $128.54M | $134.40M | $125.67M | $132.66M | $119.78M | $110.01M | $104.57M | $101.87M |
| SG&A expense | $78.90M | $86.24M | $81.02M | $82.33M | $68.52M | $76.29M | $71.05M | $76.34M |
| Operating income | $49.64M | $48.16M | $44.65M | $50.33M | $51.26M | $33.72M | $33.52M | $25.53M |
| Interest expense | $12.25M | $10.71M | $10.68M | $12.48M | $12.54M | $9.03M | $9.65M | $9.78M |
| Pretax income | $38.78M | $32.34M | $32.31M | $36.42M | $36.27M | $23.85M | $29.69M | $4.84M |
| Income tax | $9.26M | $10.63M | $8.29M | $8.97M | $9.74M | $6.62M | $8.81M | $1.65M |
| Net income | $29.52M | $21.71M | $24.02M | $27.46M | $26.53M | $17.22M | $20.88M | $3.19M |
| EBITDA | $63.22M | $61.50M | $57.10M | $63.22M | $64.09M | $46.13M | $46.13M | $37.11M |
| EPS (basic) | 0.73 | — | 0.59 | 0.68 | 0.65 | — | 0.52 | 0.08 |
| EPS (diluted) | 0.72 | — | 0.59 | 0.67 | 0.65 | — | 0.51 | 0.08 |
| Dividends declared per share | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| Weighted avg. shares (diluted) | 40.96M | — | 41.04M | 40.96M | 40.88M | — | 40.71M | 40.72M |
| Balance sheet | ||||||||
| Cash & equivalents | $75.55M | $61.42M | $54.93M | $55.49M | $72.77M | $68.04M | $60.35M | $67.07M |
| Short-term investments | $7.58M | $20.57M | $22.52M | $19.02M | $12.50M | $9.00M | $10.00M | $0 |
| Receivables | $221.71M | $238.79M | $221.55M | $215.87M | $217.90M | $227.98M | $197.52M | $191.79M |
| Inventory | $567.14M | $534.88M | $539.70M | $517.35M | $471.77M | $444.43M | $448.39M | $427.22M |
| Current assets | $945.17M | $935.51M | $894.07M | $862.18M | $835.80M | $810.61M | $776.02M | $746.15M |
| PP&E, net | $372.73M | $369.17M | $359.27M | $355.38M | $354.78M | $354.69M | $336.09M | $337.66M |
| Goodwill | $60.03M | $60.05M | $59.89M | $59.81M | $59.71M | $59.65M | $54.57M | $54.55M |
| Intangibles | $28.30M | $30.05M | $31.68M | $33.07M | $34.96M | $36.47M | $37.77M | $39.89M |
| Total assets | $1.51B | $1.50B | $1.45B | $1.41B | $1.39B | $1.36B | $1.32B | $1.29B |
| Current liabilities | $295.79M | $316.47M | $281.87M | $282.37M | $270.14M | $293.47M | $266.48M | $233.25M |
| Short-term debt | $25.02M | $25.02M | $22.83M | $20.64M | $18.44M | $16.25M | $16.25M | $16.25M |
| Long-term debt | $585.85M | $591.77M | $597.68M | $603.60M | $609.52M | $615.43M | $619.16M | $622.88M |
| Total debt | $610.88M | $616.79M | $620.52M | $624.24M | $627.96M | $631.68M | $635.41M | $639.13M |
| Total liabilities | $1.10B | $1.12B | $1.08B | $1.07B | $1.07B | $1.08B | $1.05B | $1.04B |
| Shareholders' equity | $417.67M | $385.48M | $361.83M | $332.36M | $311.68M | $285.68M | $265.99M | $246.80M |
| Net debt | $535.33M | $555.38M | $565.59M | $568.75M | $555.19M | $563.65M | $575.05M | $572.06M |
| Cash flow statement | ||||||||
| Operating cash flow | $26.08M | $24.09M | $16.21M | $19.35M | $9.30M | $21.27M | $43.15M | $3.08M |
| Capital expenditure | $18.78M | $18.87M | $15.32M | $11.10M | $13.81M | $13.14M | $7.75M | $7.82M |
| Free cash flow | $7.30M | $5.22M | $890,000 | $8.26M | -$4.50M | $8.13M | $35.41M | -$4.75M |
| Investing cash flow | -$5.95M | -$16.45M | -$16.81M | -$17.18M | -$21.01M | -$7.03M | -$18.25M | -$260.47M |
| Financing cash flow | -$5.63M | -$1.61M | -$2.30M | -$18.98M | $16.34M | -$7.77M | -$32.22M | $276.32M |
| Depreciation & amortization | $13.58M | $13.35M | $12.45M | $12.89M | $12.83M | $12.41M | $12.62M | $11.57M |
| Stock-based compensation | $804,000 | $413,000 | $411,000 | $434,000 | $339,000 | $179,000 | $179,000 | $180,000 |
| Dividends paid | $4.87M | $4.87M | $4.87M | $4.86M | $4.86M | $4.86M | $4.87M | $4.86M |
Free plan shows the latest 8 periods; Pro shows all 57 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.